Guselkumab as a Possible New Treatment for Psoriasis
Main Article Content
Abstract
Introduction: In Mexico it affects approximately 2 million people, with a significant impact on quality of life and difficult to manage.
Theoretical framework: The lesion it causes is round, salmon-pink papules and plaques, located on knees, elbows and scalp. The diagnosis is mainly clinical and the treatment will depend on the affected body surface and the location. The drugs considered first line are topical and second line drugs are used systemically, which in many occasions have adverse effects that make attachment difficult.
Guselkumab, a drug approved in 2017, is an IgG1 that blocks the p19 subunit of IL-23.
Discussion: Guselkumab, which is a monoclonal antibody, provides better patient outcomes compared to the drugs used in current therapeutics.
There is little information currently available on Guselkumab since it has only recently been approved, but in all studies it has shown to be superior to other monoclonal antibodies, the main disadvantage being that it is not currently available in Mexico and the long administration time.
Conclusion:Researching new drugs helps us to provide the patient with a treatment with the least amount of adverse effects, achieving greater adherence and better control of the disease.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Arenas Guzman R. Dermatology. 7th Ed. Mexico City: Mcgraw-Hill Interamericana; 2019.
II. Han B, Dana J, Jensen Y. Diagnosis And Management Of Psoriasis, Canadian Family Physician. 2017; 63: 278 - 285
III. Smith, Yolanda. (2018). Historical Treatment Of Psoriasis. 07/ 05 /20, From News-Medical.Net Website: Https://Www.News-Medical.Net/Health/Psoriasis-Historical-Treatment-(English).Aspx.
IV. Junko T, Sungat G, Langman M, Alexis O, Abby S. Psoriasis And Comorbid Diseases: Epidemiology, Elsevier. 2017; 76 (3); 377 - 390
V. Alexander J. F. Lazar, George F. Murphy. Skin. Robbins, Cotran. Structural And Functional Pathology. 9th Edition. Spain. Elsevier; 2015, 1141-1177.
VI. Harrison, Jameson L. Harrison Principles Of Internal Medicine. 20th Ed. Mexico D. F., [Etc:] Mcgraw-Hill; 2018.
VII. Jurado-Santa Cruz, Fermín, Páez-Agraz, Francisco, From Evidence To Experience: Concordance In The Topical Management Of Psoriasis. Medical Journal Of The Mexican Institute Of Social Security [Internet]. 2016;54(3):304-311. Retrieved From: Https://Www.Redalyc.Org/Articulo.Oa?Id=457745710007
VIII. Thomsen S, Skov L, Dodge R, Hedegaard M, Kjellberg J. Socioeconomic Costs And Health Inequalities From Psoriasis: A Cohort Study. Dermatology [Internet]. 2019 [Cited 1 Apr 2020];235(5):372-379. Available From: Https://Www.Ncbi.Nlm.Nih.Gov/Pubmed/31238322.
IX. Mendonça J, Aydin S, D'agostino M. The Use Of Ultrasonography In The Diagnosis Of Nail Disease Among Patients With Psoriasis And Psoriatic Arthritis: A Systematic Review. Advances In Rheumatology [Internet]. 2019 [Cited 1 April 2020];59(1). Available From: Http://Www.Scielo.Br/Scielo.Php?Pid=S2523-31062019000100405&Script=Sci_Arttext
X. Crowley J, Weinberg J, Wu J, Robertson A, Van Voorhees A. Treatment Of Nail Psoriasis. Jama Dermatology. 2015;151(1):87.
XI. Alisa Brandon, Asfandyar Mufti, Gary Sibbald. Diagnosis And Management Of Cutaneous Psoriasis: A Review. 2019; Advances In Skin & Wound Care & Vol. 32: 58-69. Available At: Https://Journals.Lww.Com/Aswcjournal/Fulltext/2019/02000/Diagnosis_And_Management_Of_Cutaneous_Psoriasis__A.3.Aspx.
XII. Camila Cataldi, Naiara Lourenço Mari, Marcell Alysson Batisti Lozovoy. Proinfammatory And Anti-Infammatory Cytokine Profles In Psoriasis: Use As Laboratory Biomarkers And Disease Predictors. Infammation Research (2019) 68:557-567. Disponible En:
Https://Link.Springer.Com/Article/10.1007%2fs00011-019-01238-8
XIII. National Center For Technological Excellence In Health [Cenetec]. Pharmacological Treatment For Adult Patients With Plaque Psoriasis. Mexico: Secretariat Of Health; 2013. Available At Http://Www.Cenetec.Salud.Gob.Mx/Descargas/Gpc/Catalogomaestro/Imss-696-Farmacologico_Psoriasis_En_Placas/Imss-696-13-Ger-Tx_Fx_Psoriasis_En_Placas.Pdf.
XIV. Kim A. Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham. Risankizumab Versus Ustekinumab For Moderate-To-Severe Plaque Psoriasis. N Engl J Med. 2017: 1551-1560. Available At:
Https://Www.Nejm.Org/Doi/Full/10.1056/Nejmoa1607017.
XV. Gamret A, Price A, Fertig R, Lev-Tov H, Nichols A. Complementary And Alternative Medicine Therapies For Psoriasis. Jama Dermatology. 2018;154(11):1330.
XVI. Albert. G. Wu, Jeffrey M. Weinberg. The Impact Of Diet On Psoriasis. Clinical Review. 2019; Volume 104, Issue 2s. 7-10.
XVII. Nogueira M, Torres T. Guselkumab For The Treatment Of Psoriasis - Evidence To Date. Drugs In Context 2019; 8: 212594. Https://Www.Ncbi.Nlm.Nih.Gov/Pmc/Articles/Pmc6668503/Pdf/Dic-8-212594.Pdf.
XVIII. Puig L. Guselkumab For The Treatment Of Adults With Moderate To Severe Plaque Psoriasis. Expert Review Of Clinical Immunology. 2019;15(6):589-597. [Accessed 9 May 2020] Available From: Https://Www.Tandfonline.Com/Doi/Abs/10.1080/1744666x.2019.1601014
XIX. Machado Á, Torres T. Guselkumab For The Treatment Of Psoriasis. Biodrugs. 2018;32(2):119-128. [Accessed 9 May 2020] Available From: Https://Link.Springer.Com/Article/10.1007/S40259-018-0265-6
XX. Kristian Reich, Peter Foley, Chenglong Han, Sean Mcelligott, Erik Muser, Nan Li & April W. Armstrong (2019) Guselkumab Improves Work Productivity In Patients With Moderate-To-Severe Psoriasis With Or Without Depression And Anxiety: Results From The Voyage 2 Comparator Study Versus Adalimumab, Journal Of Dermatological Treatment, Https://Www.Tandfonline.Com/Doi/Full/10.1080/09546634.2019.1628172.